Rib-X Pharmaceuticals, Inc. to Present at 10th Annual Superbugs & Superdrugs Conference
— Company to present interim results from Phase 2 trial of novel compound RX-1741
New Haven, Connecticut. April 3, 2008 — Rib-X Pharmaceuticals, Inc.,
a development-stage company focused on the discovery and development of novel antibiotics
for the treatment of antibiotic-resistant infections, today announced that Albert Collinson,
Ph.D., Chief Business Officer, will be presenting at the 10th Annual Superbugs & Superdrugs
Conference on April 9, 2008 in London, U.K. Dr. Collinson will disclose interim results from
Rib-X's Phase 2 clinical trial of RX-1741 in the treatment of uncomplicated Skin and Soft Tissue
Infections (uSSTI).
RX-1741 was discovered using Rib-X's proprietary computational tools and knowledge of the three-dimensional structure of the 50S subunit of the ribosome. An oxazolidinone antibiotic that exhibits activity against methicillin resistant Staphylococcus aureus (MRSA) and other Gram-positive organisms, RX-1741 has demonstrated both wider spectrum and stronger potency of activity than Zyvox® (linezolid), the only currently marketed product in this compound class.
The uSSTI study will enroll approximately 150 patients in study centers across the U.S. The Company intends to release final data from all patients during the first half of 2008.
About Rib-X Pharmaceuticals
Rib-X Pharmaceuticals, Inc. is a product driven small molecule drug discovery and development company focused on the structure based design of new classes of antibiotics. The Company's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in the fundamental process of protein synthesis. Many known, commercially valuable antibiotics bind to the ribosome, including those used to treat both community acquired and hospital acquired pathogens. The Company's integrated research strategy, which combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology, and biochemistry, allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinctive new antibiotic classes. The Company currently has two programs in human clinical trials, the radezolid (RX-1741) designer oxazolidinone program as an oral/IV agent to treat serious hospital Gram-positive infections and the delafloxacin, (RX-3341) program, a next generation fluoroquinolone, active against a broad spectrum of bacteria, including methicillin resistant Staphylococcus aureus. Additionally, the Company has multiple drug discovery programs. The first of these is an exciting discovery program that is well on its way toward the identification of new chemical classes of antibiotics active against multi-drug resistant Gram-negative bacteria in the hospital. The second of these programs is focused on design and development of an IV and orally active macrolide for treatment of infections in the nursing home and hospital setting, including those caused by MRSA and enterococci. Radezolid and the multiple discovery programs derive from Rib-X's proprietary use of the ribosome structure and computational tools.
RX-1741 was discovered using Rib-X's proprietary computational tools and knowledge of the three-dimensional structure of the 50S subunit of the ribosome. An oxazolidinone antibiotic that exhibits activity against methicillin resistant Staphylococcus aureus (MRSA) and other Gram-positive organisms, RX-1741 has demonstrated both wider spectrum and stronger potency of activity than Zyvox® (linezolid), the only currently marketed product in this compound class.
uSSTI Study Design
The uSSTI study is a Phase 2, multicenter, randomized, open-label, comparative study to evaluate
the safety and efficacy of RX-1741 versus linezolid in the outpatient treatment of adults with uSSTI.
The study assesses the efficacy, safety and tolerability of a once or twice daily dose of RX-1741
compared to a twice daily dose of linezolid. Dosing is given for five to ten days for the
treatment of ambulatory patients with uSSTI.
The uSSTI study will enroll approximately 150 patients in study centers across the U.S. The Company intends to release final data from all patients during the first half of 2008.
About Rib-X Pharmaceuticals
Rib-X Pharmaceuticals, Inc. is a product driven small molecule drug discovery and development company focused on the structure based design of new classes of antibiotics. The Company's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in the fundamental process of protein synthesis. Many known, commercially valuable antibiotics bind to the ribosome, including those used to treat both community acquired and hospital acquired pathogens. The Company's integrated research strategy, which combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology, and biochemistry, allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinctive new antibiotic classes. The Company currently has two programs in human clinical trials, the radezolid (RX-1741) designer oxazolidinone program as an oral/IV agent to treat serious hospital Gram-positive infections and the delafloxacin, (RX-3341) program, a next generation fluoroquinolone, active against a broad spectrum of bacteria, including methicillin resistant Staphylococcus aureus. Additionally, the Company has multiple drug discovery programs. The first of these is an exciting discovery program that is well on its way toward the identification of new chemical classes of antibiotics active against multi-drug resistant Gram-negative bacteria in the hospital. The second of these programs is focused on design and development of an IV and orally active macrolide for treatment of infections in the nursing home and hospital setting, including those caused by MRSA and enterococci. Radezolid and the multiple discovery programs derive from Rib-X's proprietary use of the ribosome structure and computational tools.
| Media/Investor Contact Information |
|---|
|
Gina Nugent
The Yates Network 617.460.3579 gina@theyatesnetwork.com |